Литература к разделу
1. Mitsias DI, Xepapadaki P, Makris M, Papadopoulos NG. Immunotherapy in allergic diseases – improved understanding and innovation for enhanced effectiveness. Curr Opin Immunol. 2020;66:1—8. doi:10.1016/j.coi.2020.02.005
2. Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc Biol Sci. 2015;282 (1821):20143085. doi:10.1098/rspb.2014.3085
3. Yu JC, Khodadadi H, Malik A, et al. Innate Immunity of Neonates and Infants. Front Immunol. 2018;9:1759. Published 2018 Jul 30. doi:10.3389/fimmu.2018.01759
4. Belderbos M, Levy O, Bont L. Neonatal innate immunity in allergy development. Curr Opin Pediatr. 2009;21 (6):762—769. doi:10.1097/MOP.0b013e3283325e3a
5. Arasi S, Corsello G, Villani A, Pajno GB. The future outlook on allergen immunotherapy in children: 2018 and beyond. Ital J Pediatr. 2018;44 (1):80. Published 2018 Jul 11. doi:10.1186/s13052-018-0519-4
6. Dhami S, Nurmatov U, Arasi S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. Allergy. 2017;72 (11):1597—1631. doi:10.1111/all.13201
7. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010; (12):CD002893. Published 2010 Dec 8. doi:10.1002/14651858.CD002893
8. Masuyama K, Okamoto Y, Okamiya K, et al. Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet in Japanese children. Allergy. 2018;73 (12):2352—2363. doi:10.1111/all.13544
9. Frati F, Scurati S, Puccinelli P, et al. Development of an allergen extract for sublingual immunotherapy – evaluation of Staloral. Expert Opin Biol Ther. 2009;9 (9):1207—1215. doi:10.1517/14712590903146869
10. Valovirta E, Petersen TH, Piotrowska T, et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol. 2018;141 (2):529—538.e13. doi:10.1016/j. jaci.2017.06.014
11. Huoman J, Papapavlou G, Pap A, Alm J, Nilsson LJ, Jenmalm MC. Sublingual immunotherapy alters salivary IgA and systemic immune mediators in timothy allergic children. Pediatr Allergy Immunol. 2019;30 (5):522—530. doi:10.1111/pai.13047
12. Fiocchi A, Pajno G, La Grutta S, et al. Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years. Ann Allergy Asthma Immunol. 2005;95 (3):254—258. doi:10.1016/S1081—1206 (10) 61222—7
13. Agostinis F, Tellarini L, Canonica GW, Falagiani P, Passalacqua G. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy. 2005;60:133.
14. Halken S, Larenas-Linnemann D, Roberts G, et al. EAACI guidelines on allergen immunotherapy: Prevention of allergy. Pediatr Allergy Immunol. 2017;28 (8):728—745. doi:10.1111/pai.12807
15. Kristiansen M, Dhami S, Netuveli G, et al. Allergen immunotherapy for the prevention of allergy: A systematic review and meta-analysis. Pediatr Allergy Immunol. 2017;28 (1):18—29. doi:10.1111/pai.12661
16. Zielen S, Devillier P, Heinrich J, Richter H, Wahn U. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real-world database analysis. Allergy. 2018;73 (1):165—177. doi:10.1111/all.13213
17. Sahin E, Dizdar D, Dinc ME, Cirik AA. Long-term effects of allergen-specific subcutaneous immunotherapy for house dust mite induced allergic rhinitis. J Laryngol Otol. 2017;131 (11):997—1001. doi:10.1017/S0022215117002110
18. Zolkipli Z, Roberts G, Cornelius V, et al. Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood. J Allergy Clin Immunol. 2015;136 (6):1541—1547.e11. doi:10.1016/j. jaci.2015.04.045
19. Marogna M, Tomassetti D, Bernasconi A, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol. 2008;101 (2):206—211. doi:10.1016/s1081—1206 (10) 60211—6
20. Szépfalusi Z, Bannert C, Ronceray L, et al. Preventive sublingual immunotherapy in preschool children: first evidence for safety and pro-tolerogenic effects. Pediatr Allergy Immunol. 2014;25 (8):788—795. doi:10.1111/pai.12310
21. Kristiansen M, Dhami S, Netuveli G, et al. Allergen immunotherapy for the prevention of allergy: A systematic review and meta-analysis. Pediatr Allergy Immunol. 2017;28 (1):18—29. doi:10.1111/pai.12661
22. Didier A, Wahn U, Horak F, Cox LS. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience. Expert Review of Clinical Immunology. 2014;10 (10):1309—1324. doi:10.1586/1744666X.2014.957677
4.
Стандартизация аллергенов
Ключевые положения
1. Не существует единых правил стандартизации аллергенов.
2. Преимуществом для использования обладают аллергены, стандартизированные биологическим способом.
3. Производители используют различные системы обозначения активности аллергенов. Нет соответствия